Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan(La Jolla Institute for Immunology), José Mateus(La Jolla Institute for Immunology), Yu Kato(La Jolla Institute for Immunology), Kathryn M. Hastie(La Jolla Institute for Immunology), Esther Dawen Yu(La Jolla Institute for Immunology), Caterina E. Faliti(La Jolla Institute for Immunology), Alba Grifoni(La Jolla Institute for Immunology), Sydney I. Ramirez(La Jolla Institute for Immunology), Sonya Haupt(La Jolla Institute for Immunology), April Frazier(La Jolla Institute for Immunology), Catherine Nakao(La Jolla Institute for Immunology), Vamseedhar Rayaprolu(La Jolla Institute for Immunology), Stephen A. Rawlings(University of California San Diego), Bjoern Peters(La Jolla Institute for Immunology), Florian Krammer(Icahn School of Medicine at Mount Sinai), Viviana Simon(Icahn School of Medicine at Mount Sinai), Erica Ollmann Saphire(La Jolla Institute for Immunology), Davey M. Smith(University of California San Diego), Daniela Weiskopf(La Jolla Institute for Immunology), Alessandro Sette(La Jolla Institute for Immunology), Shane Crotty(La Jolla Institute for Immunology)
Science
January 6, 2021
Cited by 3,002Open Access
Full Text

Abstract

Variable memory Immune memory against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) helps to determine protection against reinfection, disease risk, and vaccine efficacy. Using 188 human cases across the range of severity of COVID-19, Dan et al. analyzed cross-sectional data describing the dynamics of SARS-CoV-2 memory B cells, CD8 + T cells, and CD4 + T cells for more than 6 months after infection. The authors found a high degree of heterogeneity in the magnitude of adaptive immune responses that persisted into the immune memory phase to the virus. However, immune memory in three immunological compartments remained measurable in greater than 90% of subjects for more than 5 months after infection. Despite the heterogeneity of immune responses, these results show that durable immunity against secondary COVID-19 disease is a possibility for most individuals. Science , this issue p. eabf4063


Related Papers

No related papers found

Powered by citation graph analysis